In summary, Res overcame STAT3/VEGF‐mediated MDR by suppressing the inflammatory microenvironment, which provided a sound basis for SCLC treatment using Res alone or in combination with other agents in clinical trials. The gene discussed is STAT3; the disease is small cell lung carcinoma.